Early Access — free while we kick the tires
EdgarHawk

Chudova Darya

Chief Technology Officer

Officer
2 filings analyzed · 1 company · Latest 2025-12-17

Companies

Company Buys Sells Direction
Guardant Health, Inc. GH 0 5 Net selling

Activity

December 2025
medium
Sell
5,451 shares
$567,132
Significance 5/10

CTO Chudova Darya sold 5,451 shares of GH at $104.04 on 2025-12-15, reducing stake 43.7%

Chudova Darya, CTO, sold 5,451 shares (reducing holdings by -43.7%) at $104.04 on 2025-12-15, with post-transaction holdings of 7,012 shares. The stock is currently trading at $97.47, down 12.4% from its 52-week high of $111.25. The company reported a net loss of $-92.7M on $265.2M quarterly revenue and remains unprofitable on a full-year basis, despite 31.0% annual revenue growth. This substantial reduction in the CTO's stake occurs within the context of negative net income and earlier sales at the same ticker (two separate sells on 2025-12-08), warranting examination of whether fundamental operational challenges are driving the reduction.

medium
Sell
22,935 shares
$2,417,980
Significance 6/10

CTO Chudova sells 22,935 shares ($2.4M) in two transactions at $105–$106 while GH unprofitable

Darya Chudova, Chief Technology Officer, executed 2 separate sales totaling 22,935 shares for $2,417,979.82 at prices ranging from $105.04 to $106.00, reducing her holdings by 29.6% to 54,480 shares. This occurs amid a company-wide unprofitable fiscal year (net income was negative) despite strong 31.0% annual revenue growth and a 90-day stock surge of +80.7%, which may have created a window for liquidation. The sale volume is material relative to her post-transaction position, and the blended average price of $105.43 sits 2.8% above the current price of $102.62, occurring near the stock's recent 52-week range top. The transaction provides concrete data on insider valuation near a peak but does not, by itself, indicate forward-looking conviction or concern.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access